Drug Trial Radar · NCT06097832
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Jun 5, 2024
Primary completion
Dec 2026
Study completion Jan 2039
Sponsor
- Lead sponsor
- Nexcella Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Immix Biopharma, Inc.
- First posted
- Oct 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Conditions
- Light Chain (AL) Amyloidosis
Interventions
NXC-201 CAR-TBiological
NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryopreservation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Related Adverse EventsTime frame: 24 months
- Number of Participants with Adverse Events by Severity as Assessed by CTCAE v5.0Time frame: 24 months
- To confirm the maximum tolerated dose (MTD)Time frame: 24 months
- To confirm the recommended phase 2 dose (RP2D)Time frame: 24 months
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Sutter Health Alta Bates
Berkeley, California
City of Hope
Duarte, California
University of California Los Angeles
Los Angeles, California
University of California Davis Medical Center
Sacramento, California
Stanford University
Stanford, California
Winship Cancer Institute, Emory University
Atlanta, Georgia
The University of Kansas Cancer Center
Fairway, Kansas
Tufts Medical Center
Boston, Massachusetts
Boston University Medical Center
Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota
Washington University Siteman Cancer Center
St Louis, Missouri
Memorial Sloan Kettering Comprehensive Cancer Center
New York, New York
University of Cincinnati Cancer Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Baptist Memorial Hospital
Memphis, Tennessee
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah
Swedish Cancer Institute
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.